Idexx Laboratories (IDXX) stock
Last close $676.21 on 2026-11-20 (-1.95%) · Sector: Healthcare
Idexx Laboratories makes diagnostic tests, lab analyzers, and software that veterinarians use to check pets for illness and track their health. It earns most of its money from recurring sales of test supplies and services to animal clinics around the world, plus the equipment that runs those tests.
Idexx is still growing its sales, with revenue up 11.8% over the past year and a healthy operating margin of 32.4%. The stock has lagged the S&P 500 over the past year, falling 10.1% while the index rose 3.15%, and it is 12.2% below its 52-week high. Insiders sold about $28.6 million of stock over the last 90 days and made no purchases, and the stock rose the day after only 2 of its 4 recent earnings reports, with one big 21.8% jump.
Key numbers
- Market cap: $53.5B
- Revenue (last 12 months): $4.66B
- Revenue growth: +11.8%
- Gross margin: 62.6%
- Operating margin: 32.4%
- P/S: 11.5
- Debt to equity: 0.16
- Current ratio: 1.19
Quality score
Overall 54/100 · growth 39 · profitability 59 · financial health 63 · value None
Performance and risk
1-year return -10.1% vs S&P 500 +3.1% · volatility 36.4% (S&P 500 14.2%) · largest drop -34.2% · beta 0.73
Stock move the day after earnings
- 2026-02-02: -4.6%
- 2026-05-05: -0.0%
- 2026-08-04: +3.6%
- 2026-11-02: +21.8%
Insider trades (12 months)
Bought $0.0M · sold $58.4M
IDXX stock research · IDXX options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.